3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Urinary Bladder Neoplasms
1
Urethral Neoplasms
1
Ureteral Neoplasms
1
Carcinoma, Transitional Cell
1
Interventions
pembrolizumab
1268
Specimen Handling
871
Carboplatin
831
Magnetic Resonance Spectroscopy
805
Cyclophosphamide
802
Cisplatin
728
Nivolumab
658
Paclitaxel
630
Radiotherapy
573
Gemcitabine
571
Biopsy
529
Bevacizumab
476
Dexamethasone
440
fludarabine
406
Docetaxel
378
venetoclax
370
Oxaliplatin
365
Capecitabine
358
Fluorouracil
355
atezolizumab
344
durvalumab
333
Rituximab
332
Doxorubicin
317
Radiosurgery
309
Pemetrexed
306
Drug Therapy
302
Ipilimumab
294
Standard of Care
293
Etoposide
284
Radiation
281
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
tamibarotene
×
1 year
×
Clear all
NCT06983210
2025-08-14
GRAPE
Nagoya University
Phase 2
Recruiting
43 enrolled